PRECISION OPTICS CORPORATION, INC.
POCIDrugs in Pipeline
21
Phase 3 Programs
5
Upcoming Catalysts
6
Next Catalyst
Mar 23, 2026
6wMarket Overview
Stock performance and market intelligence
6 upcoming, 0 past
PRAX-562 Phase 3 Results Expected
Primary completion for PRAX-562 trial (NCT05818553) in SCN2A Encephalopathy
Source1mg elsunersen Phase 3 Results Expected
Primary completion for 1mg elsunersen trial (NCT07019922) in Epileptic Encephalopathy
Source1.0mg/kg/day PRAX-562 Phase 3 Results Expected
Primary completion for 1.0mg/kg/day PRAX-562 trial (NCT07010471) in Developmental and Epileptic Encephalopathy 1
SourceCD19 and CD22 targeted prime CAR-T cells Phase 2 Results Expected
Primary completion for CD19 and CD22 targeted prime CAR-T cells trial (NCT04781634) in B-ALL
SourceBCMA targeted prime CAR-T cells Phase 2 Results Expected
Primary completion for BCMA targeted prime CAR-T cells trial (NCT04776330) in Multiple Myeloma
SourceBCMA CAR-T cells Phase 2 Results Expected
Primary completion for BCMA CAR-T cells trial (NCT04271644) in Multiple Myeloma
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
1.0mg/kg/day PRAX-562
Developmental and Epileptic Encephalopathy 1
PRAX-562
SCN2A Encephalopathy
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
Focal Seizure
PRAX-114
Major Depressive Disorder
1mg elsunersen
Epileptic Encephalopathy
CD19 and CD22 targeted prime CAR-T cells
B-ALL
PRAX-222 - Initial Dose
SCN2A-DEE
CEA-targeted CAR-T cells
Gastric Cancer
ICT-107
Glioblastoma Multiforme
PDI-192
Atopic Dermatitis
NEO-201 in combination with pembrolizumab
Non Small Cell Lung Cancer
BCMA CAR-T cells
Multiple Myeloma
10 mg PRAX-114
Major Depressive Disorder
CD123 targeted CAR-NK cells
Acute Myeloid Leukemia
30mg PRAX-628
Focal Onset Seizure
100 mg PRAX-944
Essential Tremor
BCMA targeted prime CAR-T cells
Multiple Myeloma
NPC-1C/NEO-102
Metastatic Pancreatic Cancer
Part A: 20 and 40 mg PRAX-944
Essential Tremor
pCAR-19B cells
Acute Lymphoblastic Leukemia
donor-derived NK cell infusion
Non-small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
1.0mg/kg/day PRAX-562 | Phase 3 | Developmental and Epileptic Encephalopathy 1 | - |
PRAX-562 | Phase 3 | SCN2A Encephalopathy | - |
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks | Phase 3 | Focal Seizure | - |
PRAX-114 | Phase 3 | Major Depressive Disorder | - |
1mg elsunersen | Phase 3 | Epileptic Encephalopathy | - |
CD19 and CD22 targeted prime CAR-T cells | Phase 2 | B-ALL | - |
PRAX-222 - Initial Dose | Phase 2 | SCN2A-DEE | - |
CEA-targeted CAR-T cells | Phase 2 | Gastric Cancer | - |
ICT-107 | Phase 2 | Glioblastoma Multiforme | - |
PDI-192 | Phase 2 | Atopic Dermatitis | - |
NEO-201 in combination with pembrolizumab | Phase 2 | Non Small Cell Lung Cancer | - |
BCMA CAR-T cells | Phase 2 | Multiple Myeloma | - |
10 mg PRAX-114 | Phase 2 | Major Depressive Disorder | - |
CD123 targeted CAR-NK cells | Phase 2 | Acute Myeloid Leukemia | - |
30mg PRAX-628 | Phase 2 | Focal Onset Seizure | - |
100 mg PRAX-944 | Phase 2 | Essential Tremor | - |
BCMA targeted prime CAR-T cells | Phase 2 | Multiple Myeloma | - |
NPC-1C/NEO-102 | Phase 2 | Metastatic Pancreatic Cancer | - |
Part A: 20 and 40 mg PRAX-944 | Phase 2 | Essential Tremor | - |
pCAR-19B cells | Phase 2 | Acute Lymphoblastic Leukemia | - |
donor-derived NK cell infusion | Phase 2 | Non-small Cell Lung Cancer | - |
Regulatory & News
Approvals, filings, and latest developments